151 related articles for article (PubMed ID: 34443335)
41. Ensemble-based ADME-Tox profiling and virtual screening for the discovery of new inhibitors of the Leishmania mexicana cysteine protease CPB2.8ΔCTE.
Scala A; Rescifina A; Micale N; Piperno A; Schirmeister T; Maes L; Grassi G
Chem Biol Drug Des; 2018 Feb; 91(2):597-604. PubMed ID: 29045053
[TBL] [Abstract][Full Text] [Related]
42. An Updated Review on SARS-CoV-2 Main Proteinase (M
Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134
[TBL] [Abstract][Full Text] [Related]
43. New peptidic cysteine protease inhibitors derived from the electrophilic alpha-amino acid aziridine-2,3-dicarboxylic acid.
Schirmeister T
J Med Chem; 1999 Feb; 42(4):560-72. PubMed ID: 10052963
[TBL] [Abstract][Full Text] [Related]
44. Reactivity and binding mode of disulfiram, its metabolites, and derivatives in SARS-CoV-2 PL
Nogara PA; Omage FB; Bolzan GR; Delgado CP; Orian L; Rocha JBT
J Mol Model; 2022 Oct; 28(11):354. PubMed ID: 36222962
[TBL] [Abstract][Full Text] [Related]
45. Substitution-Induced Mechanistic Switching in S
Zimmer C; Brauer J; Ferenc D; Meyr J; Müller P; Räder HJ; Engels B; Opatz T; Schirmeister T
Molecules; 2024 Jun; 29(11):. PubMed ID: 38893535
[TBL] [Abstract][Full Text] [Related]
46. Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L.
Falgueyret JP; Oballa RM; Okamoto O; Wesolowski G; Aubin Y; Rydzewski RM; Prasit P; Riendeau D; Rodan SB; Percival MD
J Med Chem; 2001 Jan; 44(1):94-104. PubMed ID: 11141092
[TBL] [Abstract][Full Text] [Related]
47. Understanding the binding mechanism for potential inhibition of SARS-CoV-2 Mpro and exploring the modes of ACE2 inhibition by hydroxychloroquine.
Choudhury M; Dhanabalan AK; Goswami N
J Cell Biochem; 2022 Feb; 123(2):347-358. PubMed ID: 34741481
[TBL] [Abstract][Full Text] [Related]
48. 3CL Protease Inhibitors with an Electrophilic Arylketone Moiety as Anti-SARS-CoV-2 Agents.
Konno S; Kobayashi K; Senda M; Funai Y; Seki Y; Tamai I; Schäkel L; Sakata K; Pillaiyar T; Taguchi A; Taniguchi A; Gütschow M; Müller CE; Takeuchi K; Hirohama M; Kawaguchi A; Kojima M; Senda T; Shirasaka Y; Kamitani W; Hayashi Y
J Med Chem; 2022 Feb; 65(4):2926-2939. PubMed ID: 34313428
[TBL] [Abstract][Full Text] [Related]
49. The medicinal chemistry of the cathepsin cysteine proteases.
Masuya K; Teno N
Curr Top Med Chem; 2010; 10(7):695. PubMed ID: 20392199
[No Abstract] [Full Text] [Related]
50. Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.
Amin SA; Banerjee S; Ghosh K; Gayen S; Jha T
Bioorg Med Chem; 2021 Jan; 29():115860. PubMed ID: 33191083
[TBL] [Abstract][Full Text] [Related]
51. Inhibition of the cathepsin cysteine proteases B and K by square-planar cycloaurated gold(III) compounds and investigation of their anti-cancer activity.
Zhu Y; Cameron BR; Mosi R; Anastassov V; Cox J; Qin L; Santucci Z; Metz M; Skerlj RT; Fricker SP
J Inorg Biochem; 2011 May; 105(5):754-62. PubMed ID: 21481817
[TBL] [Abstract][Full Text] [Related]
52. Repurposing simeprevir, calpain inhibitor IV and a cathepsin F inhibitor against SARS-CoV-2 and insights into their interactions with M
J A; Francis D; C S S; K G A; C S; Variyar EJ
J Biomol Struct Dyn; 2022 Jan; 40(1):325-336. PubMed ID: 32873185
[TBL] [Abstract][Full Text] [Related]
53. Docking Paradigm in Drug Design.
Sulimov VB; Kutov DC; Taschilova AS; Ilin IS; Tyrtyshnikov EE; Sulimov AV
Curr Top Med Chem; 2021; 21(6):507-546. PubMed ID: 33292135
[TBL] [Abstract][Full Text] [Related]
54. Discovery of New Hydroxyethylamine Analogs against 3CL
Kumar S; Sharma PP; Shankar U; Kumar D; Joshi SK; Pena L; Durvasula R; Kumar A; Kempaiah P; Poonam ; Rathi B
J Chem Inf Model; 2020 Dec; 60(12):5754-5770. PubMed ID: 32551639
[TBL] [Abstract][Full Text] [Related]
55. Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants -
Shree P; Mishra P; Selvaraj C; Singh SK; Chaube R; Garg N; Tripathi YB
J Biomol Struct Dyn; 2022 Jan; 40(1):190-203. PubMed ID: 32851919
[TBL] [Abstract][Full Text] [Related]
56. Estimating the binding energetics of reversible covalent inhibitors of the SARS-CoV-2 main protease: an
Awoonor-Williams E
Phys Chem Chem Phys; 2022 Oct; 24(38):23391-23401. PubMed ID: 36128834
[TBL] [Abstract][Full Text] [Related]
57. Mass spectrometry reveals potential of β-lactams as SARS-CoV-2 M
Malla TR; Tumber A; John T; Brewitz L; Strain-Damerell C; Owen CD; Lukacik P; Chan HTH; Maheswaran P; Salah E; Duarte F; Yang H; Rao Z; Walsh MA; Schofield CJ
Chem Commun (Camb); 2021 Feb; 57(12):1430-1433. PubMed ID: 33462575
[TBL] [Abstract][Full Text] [Related]
58. Terpyridine platinum(II) complexes inhibit cysteine proteases by binding to active-site cysteine.
Lo YC; Su WC; Ko TP; Wang NC; Wang AH
J Biomol Struct Dyn; 2011 Oct; 29(2):267-82. PubMed ID: 21875148
[TBL] [Abstract][Full Text] [Related]
59. In silico analysis of selected alkaloids against main protease (M
Garg S; Roy A
Chem Biol Interact; 2020 Dec; 332():109309. PubMed ID: 33181114
[TBL] [Abstract][Full Text] [Related]
60. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents.
Mody V; Ho J; Wills S; Mawri A; Lawson L; Ebert MCCJC; Fortin GM; Rayalam S; Taval S
Commun Biol; 2021 Jan; 4(1):93. PubMed ID: 33473151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
